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Aims Previously, low high-density lipoprotein (HDL) cholesterol was found to be one of the strongest predictors of
mortality and/or heart failure (HF) hospitalisation in patients with HF. We therefore performed in-depth investigation
of the multifunctional HDL proteome to reveal underlying pathophysiological mechanisms explaining the association
between HDL and clinical outcome.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Methods
and results
We selected a cohort of 90 HF patients with 1:1 cardiovascular death/survivor ratio from BIOSTAT-CHF. A novel
optimised protocol for selective enrichment of lipoproteins was used to prepare plasma. Enriched lipoprotein content
of samples was analysed using high resolution nanoscale liquid chromatography-mass spectrometry-based proteomics,
utilising a label free approach. Within the HDL proteome, 49 proteins significantly differed between deaths and
survivors. An optimised model of 12 proteins predicted death with 76% accuracy (Nagelkerke R2=0.37, P < 0.001).
The strongest contributors to this model were filamin-A (related to crosslinking of actin filaments) [odds ratio (OR)
0.31, 95% confidence interval (CI) 0.15–0.61, P = 0.001] and pulmonary surfactant-associated protein B (related
to alveolar capillary membrane function) (OR 2.50, 95% CI 1.57–3.98, P < 0.001). The model predicted mortality
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with an area under the curve of 0.82 (95% CI 0.77–0.87, P < 0.001). Internal cross validation resulted in 73.3± 7.2%
accuracy.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Conclusion This study shows marked differences in composition of the HDL proteome between HF survivors and deaths.
The strongest differences were seen in proteins reflecting crosslinking of actin filaments and alveolar capillary
membrane function, posing potential pathophysiological mechanisms underlying the association between HDL and
clinical outcome in HF.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Introduction
Several studies showed that lower high-density lipoprotein (HDL)
cholesterol was associated with a higher incidence of heart failure
(HF),1 worsening of HF,2 and mortality and HF hospitalisation in
patients with established HF.2–5 We recently studied predictors
of clinical outcome in two large European cohorts of patients
with HF [A systems BIOlogy Study to TAilored Treatment in
Chronic Heart Failure (BIOSTAT-CHF)]. Low HDL cholesterol
was found to be amongst the strongest independent predictors
of death and/or HF hospitalisation.6 The exact pathophysiological
mechanisms underlying the association between HDL and HF are
however unknown.
Technological developments and the use of mass spectrome-
try have strongly increased our understanding of the proteomic
diversity of HDL. Besides the well-known function in reverse
cholesterol transport, HDL carries many other constituents. Pre-
vious studies have identified over 90 proteins that are con-
sistently co-expressed in variable amounts attached to HDL
particles, consisting of apolipoproteins, lipid transfer proteins,
enzymes, acute-phase response proteins, complement compo-
nents, haemostasis proteins and several others. The functions
of HDL are therefore multifold: it possesses anti-inflammatory,
antioxidant, anti-infective, antithrombotic, and atheroprotective
capacities and exerts effects on endothelial function.7
We hypothesised that further in-depth investigation of the
multifunctional HDL proteome could reveal possible underlying
pathophysiological mechanisms of HDL in HF that can help us
understand its clinical value in HF. Therefore, this study aims to
investigate differences in HDL proteome composition in HF that
relate to a worse prognosis in HF.
Materials and methods
Patient population
This study was conducted with patients selected from the
BIOSTAT-CHF cohort, which has been described in detail before.8
In brief, BIOSTAT-CHF was an investigator-driven multicentre clinical
study consisting of 2516 patients, which aimed to identify patients
with a poor outcome despite currently recommended treatment
using a systems biology approach that incorporates demograph-
ics, gender, biomarkers, genetics and proteomics. Patients were

































































. HF, which was confirmed by left ventricular ejection fraction ≤40%
and/or brain natriuretic peptide (BNP) >400 pg/mL or N-terminal
pro BNP (NT-proBNP) >2000 pg/mL. All patients recruited in
BIOSTAT-CHF gave written informed consent to participate in the
study. BIOSTAT-CHF was conducted in concordance with the decla-
ration of Helsinki, national ethics and legal requirements, as well as
relevant EU legislation. The study was approved by national and local
ethics committees.
For this study, 90 patients from BIOSTAT-CHF were selected for
a discovery cohort and matched with a 1:1 death/survivor ratio of
cardiovascular cause within a follow-up period of 12months. Patients
were furthermore matched for important prognostic criteria. The
matching criteria and randomisation procedure are shown in the
supplementary material online, Appendix S1.
Sample preparation
The detailed sample preparation protocol has been included in the
supplementary material online, Appendix S2. Lipoproteins were iso-
lated using calcium silicate matrix (commercial name Lipid Removal
Agent, Sigma-Aldrich, St. Louis, MO, USA), to separate them from
other abundant proteins in plasma which will impair proteomic
analysis. Prior to trypsin digestion, disulphide bonds were reduced
using tris (2-carboxyethyl) phosphine (TCEP, Sigma-Aldrich), cys-
teines alkylated by iodoacetamide (IAA, Sigma-Aldrich), following
denaturation using ammonium deoxycholate (ADC, 0.5%, deoxy-
cholic acid treated with neat ammonium hydroxide, Sigma-Aldrich),
thus allowing trypsin maximum access to the cleavage sites within
the protein and preventing renaturation. Trypsin (Sigma-Aldrich)
was added and the samples were incubated at 37 ∘C for 16 h.
Trypsin digestion was stopped by lowering the pH of the sam-
ple with a volume of fully concentrated formic acid (FA, final
concentration 1%, Sigma-Aldrich). Salts and other undesired impu-
rities were eliminated by solid phase extraction on EMPORE
C18 discs. A semi-pooled sample was created from 10 random
samples of the discovery cohort to serve as a quality control
(QC) sample. The QC samples were treated equal to the other
samples.
Samples were reconstituted in purified water containing FA (0.1%)
and spiked with an internal standard, MassPREP™ yeast alcohol dehy-
drogenase (ADH, Waters Corporation, Manchester, UK), with a
known amount of 50 fmol injected for each run; 1 μL of sample was
injected. All samples were analysed in triplicate. A QC was run in trip-
licate after each batch of 10 samples with an injection volume of 1 μL
for each single run. In between each patient or QC, washings were per-
formed with three different cleaning mixtures that contained isopropyl
alcohol, methanol, and FA, respectively.
© 2017 The Authors
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Table 1 Baseline characteristics of the BIOSTAT-CHF discovery cohort
Characteristics Survivors (n = 45) Deaths (n = 45) P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age, years 70.0± 9.3 69.9± 8.8 0.963
Male sex, n (%) 39 (87) 39 (87) 1.000
BMI, kg/m2 28.2± 4.8 27.5± 6.2 0.524
NYHA class III/IV, n (%) 39 (87) 35 (78) 0.524
LVEF, % 28.0± 5.7 26.3± 7.2 0.221
Systolic blood pressure, mmHg 124.5± 23.6 118.5± 21.3 0.210
Diastolic blood pressure, mmHg 73.8±13.7 72.3±11.3 0.576
Heart rate, b.p.m. 76± 20 79±15 0.440
BNP, pg/mL 409.3 (162.0–573.2) 488.4 (230.5–766.5) 0.255
eGFR, mL/min/1.73m2 56.3±17.2 53.2± 21.1 0.455
Serum creatinine, 𝜇mol/L 114.0 (98.0–133.9) 124.0 (99.7–163.5) 0.296
Total cholesterol, mmol/La 3.7 (3.3–4.5) 3.2 (2.8–4.2) 0.070
HDL cholesterol, mmol/Lb 1.1 (1.0–1.3) 0.8 (0.7–1.1) 0.004
LDL cholesterol, mmol/Lc 2.2 (1.7–3.2) 1.8 (1.5–2.8) 0.092
Diabetes, n (%) 20 (44) 18 (40) 0.670
Hypertension, n (%) 34 (76) 27 (60) 0.114
Reason for visit, n (%) 1.000
New onset of HF 3 (7) 3 (7)
Worsening HF 42 (93) 42 (93)
BMI, body mass index; BNP, brain natriuretic peptide; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; HF, heart failure; LDL, low-density lipoprotein;
LVEF, left ventricular ejection fraction; NYHA, New York Heart Association.
aData only available for 54 patients (28 survivors; 26 deaths).
bData only available for 49 patients (26 survivors; 23 deaths).
cData only available for 48 patients (25 survivors; 23 deaths).
Nanoscale liquid chromatography-
coupled mass spectrometry
Each sample was analysed on a Waters NanoAcquity system (Waters
Corporation, Milford, MA, USA). The liquid chromatography system
was coupled to a Waters Synapt G2S HDMS (Waters Corporation,
Milford, MA, USA). Data were acquired using MassLynx 4.1. Details on
the settings and methodology that were implemented are described in
the supplementary material online, Appendix S3).
Data analysis
Raw data were interrogated by Progenesis QI software (Nonlinear
Dynamics, Gateshead, UK) for data analysis. A description of the
used search criteria is included in the supplementary material online,
Appendix S3.
Progenesis QI executed label-free quantification of the identified
proteins using the Hi-N3 method as first described by Silva et al.9 Since
the samples were internally spiked, this allowed for both Hi-N relative
quantification and Hi-N absolute quantification. Analyses were focused
on Hi-N relative quantification, with the Hi-N absolute quantification
method serving as a verification back-up if needed.
Statistical analysis
Descriptive statistics were used to examine the relationship of the two
groups with clinical variables. Prior to analyses, the distribution of all
variables was checked. Data are presented as mean± standard devi-









































.. skewed variables and as frequencies (percentage) for categorical vari-
ables. A P-value of <0.05 was considered statistically significant. Con-
tinuous normally distributed variables were tested with the Student
independent t-test or analysis of variance (ANOVA), whereas skewed
variables were tested using the Kruskal–Wallis H test. Categorical vari-
ables were tested with Chi-Squared tests. To adjust for multiple testing,
a false discovery rate of 1% was implemented for biomarker selection.
Different search techniques [logistic regression and orthogonal pro-
jections to latent structures-discriminant analysis (OPLS-DA)] were
used to establish an optimised model among significant proteins for
death prediction. Logistic regression analysis of this optimised model
was adjusted for age, sex, trigger event, trigger reason, left ventricular
ejection fraction, estimated glomerular filtration rate, and cardiovas-
cular death risk score, which are explained in further detail in Appendix
S1. Statistical tests were performed with IBM SPSS Statistics version
23. SIMCA version 14 (MSK Umetrics, Sweden) was used to perform
principal component analysis and construct the S-plot. Internal cross
validation was performed using RapidMiner software version 7.4 for
candidate biomarkers. Gene Ontology analysis of proteins was exe-
cuted using the Protein ANalysis THrough Evolutionary Relationships
(PANTHER) Classification System version 11.1.10
Results
Patient characteristics
Patient characteristics of the two groups are displayed in
Table 1. Mean age was 70.0± 9.3 years in the patients who
survived and 69.9± 8.8 years in the patients who died. In both
groups, most patients were men (87%), most patients had a New
© 2017 The Authors
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Figure 1 Principal component analysis of the high-density
lipoprotein proteomes of survivors and deaths. SIMCA14 was
used to generate a 3D plot based on orthogonal projections to
latent structures discriminant analysis scores. Each data point rep-
resents a sample in the data. Each green point on the plot repre-
sents a survivor’s proteome profile and each blue point represents
a deceased patient’s proteome profile, showing the separation of
proteome profiles between survivors and deaths.
York Heart Association classification of III/IV (87% and 78% for
survivors and deaths, respectively), and HDL cholesterol levels
were higher in the survivors group [1.1 (1.0–1.3) mmol/L, as
opposed to 0.8 (0.7–1.1) mmol/L in deaths, P = 0.004]. All other
patient characteristics were not significantly different between the
two groups. Mean study participation time was 787.0±137.6 days
for survivors and 151.7± 98.7 days for deaths.
Principal component analysis
The separation of the HDL proteomes of survivors and deaths
is indicated in Figure 1. Each point on the plot represents a

























































. the patient sample analysis in triplicate. The principal component
analysis is also displayed in 2D in the supplementary material online,
Figure S1.
HDL proteome biomarkers selection
A total of 647 proteins with quantification were identified from
both groups and compared. Out of all reported HDL proteins,
as documented by the HDL Proteome Watch (initiated by the
Davidson Lab, Cincinnati, OH; database version 14/08/2015), abun-
dances of 49 HDL proteins were significantly different between
deaths and survivors (supplementary material online, Table S1).
Gene Ontology analysis of these proteins revealed involvement in
multiple biological processes, such as cellular processes (e.g. cell
communication), biological regulation (e.g. homeostatic process),
metabolic processes (e.g. lipid metabolism, protein metabolic pro-
cess), and response to stimulus (e.g. immune response, response
to stress), as shown in the supplementary material online, Figure S2.
An optimised model featuring 12 selected proteins was
established, using different search techniques, to predict death.
These 12 proteins included coagulation factor X (F10), epoxide
hydrolase (EPHX1), filamin-A (FLNA), macrophage-stimulating
protein (also called hepatocyte growth factor-like protein), pul-
monary surfactant-associated protein B (SFTPB), and serum
paraoxonase/arylesterase 1 (PON1) based on multiple regres-
sion analysis, and alpha-2-HS-glycoprotein (also called fetuin-A),
apolipoprotein A-I (APOA1), apolipoprotein A-II (APOA2),
apolipoprotein C-III (APOC3), beta-2-microglobulin, and kallis-
tatin (also called Serpin A4) based on OPLS-DA using a variable
importance in projection (VIP) value >1 as cut-off value (data not
shown). An overview with details on the proteins is provided in
Table 2.
Multiple logistic regression analysis of this set of proteins
resulted in an ability to predict death with 76% accuracy (Nagelk-
erke R2 =0.365, P-value for the model <0.001). Table 3 shows the
contribution of each protein to the prediction model, after correct-
ing for the matching criteria. The proteins that significantly con-
tributed to the prediction of death were SFTPB [odds ratio (OR)
Table 2 Proteins associated with clinical outcome in heart failure as selected by multiple approaches





. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Alpha-2-HS-glycoprotein Negative acute phase reactant Lower 1.18 0.014
Apolipoprotein A-I Anti-atherogenic, antioxidant, anti-inflammatory Lower 1.16 <0.001
Apolipoprotein A-II Anti-atherogenic, antioxidant Lower 1.28 0.022
Apolipoprotein C-III Pro-atherogenic Lower 1.58 0.008
Beta-2-microglobulin Indicator of immune activation Higher 1.17 0.045
Coagulation factor X Coagulation Higher 1.22 0.021
Epoxide hydrolase 1 Detoxification Higher 1.17 0.008
Filamin-A Crosslinks actin filaments Lower 1.19 0.011
Kallistatin Antioxidant, anti-inflammatory, anti-fibrotic Lower 1.27 <0.001
Macrophage-stimulating protein Stress response, pro-apoptotic Lower 1.26 0.034
Pulmonary surfactant-associated protein B Assembly of pulmonary surfactant Higher 1.39 0.006
Serum paraoxonase/arylesterase 1 Anti-atherogenic, antioxidant, anti-inflammatory Lower 1.20 0.006
© 2017 The Authors
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Table 3 Multiple logistic regression model for prediction of death
Protein B Wald P-value Odds ratio (95% CI)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Alpha-2-HS-glycoprotein –0.161 0.143 0.706 0.85 (0.37–1.96)
Apolipoprotein A-I –0.846 9.926 0.002 0.43 (0.25–0.73)
Apolipoprotein A-II 0.014 0.002 0.962 1.01 (0.58–1.77)
Apolipoprotein C-III –0.159 0.513 0.474 0.85 (0.55–1.32)
Beta-2-microglobulin 0.370 1.751 0.186 1.45 (0.84–2.50)
Coagulation factor X 0.735 5.123 0.024 2.09 (1.10–3.94)
Epoxide hydrolase 1 1.147 9.875 0.002 3.15 (1.54–6.44)
Filamin-A –1.186 11.350 0.001 0.31 (0.15–0.61)
Kallistatin –0.285 1.225 0.268 0.75 (0.45–1.25)
Macrophage-stimulating protein –0.198 0.626 0.429 0.82 (0.50–1.34)
Pulmonary surfactant-associated protein B 0.916 14.917 <0.001 2.50 (1.57–3.98)
Serum paraoxonase/arylesterase 1 –0.592 6.216 0.013 0.55 (0.35–0.88)
CI, confidence interval.
2.50, 95% confidence interval (CI) 1.57–3.98, P < 0.001], FLNA
(OR 0.31, 95% CI 0.15–0.61, P = 0.001), APOA1 (OR 0.43, 95%
CI 0.25–0.73, P = 0.002), EPHX1 (OR 3.15, 95% CI 1.54–6.44,
P = 0.002), PON1 (OR 0.55, 95% CI 0.35–0.88, P = 0.013), and
F10 (OR 2.09, 95% CI 1.10–3.94, P = 0.024). Associations of FLNA
and SFTPB with structural and functional parameters and biomark-
ers are presented in the supplementary material online, Table S2.
To further confirm the value of the selected proteins, a S-plot
was drafted (as presented in Figure 2) to provide a graphical
representation of both the covariance and correlation structure
between the selected proteins and the predictive score for death.
In linear regression analysis, these 12 proteins significantly pre-
dicted HDL cholesterol (P < 0.001), resulting in R2 =0.579.
When a receiver operating characteristic curve was plotted for
all selected proteins combined, this resulted in an area under the
curve of 0.820 (95% CI 0.768–0.872, P < 0.001) and a maximum
sensitivity and specificity of 0.763 and 0.756, respectively (Figure 3).
Internal cross validation resulted in 73.3± 7.2% accuracy.
Discussion
In the present study, we demonstrate that the HDL proteome is
different in HF patients who survived and those who died. The
strongest differences were seen in proteins reflecting crosslinking
of actin filaments and alveolar capillary membrane function. These
marked differences in HDL proteome composition between
deaths and survivors might reveal the pathophysiological mech-
anisms underlying the association between HDL and clinical
outcome in HF.
Previous studies investigating the HDL proteome in HF
observed differences in proteome profiles between healthy
subjects and HF patients and proteome profiles in HF patients
associated with immune response.11,12 Additionally, diminished
anti-inflammatory,13 antioxidant activity,13–15 and cholesterol
efflux capacity16 of HDL have been implicated in HF and predicted
adverse events. The present study is the first to investigate dif-
























































. in HF in a larger, well-characterised HF patient population with
well-matched subgroups, utilising state-of-the-art nanoscale liq-
uid chromatography-coupled mass spectrometry and powerful
informatics to analyse the data.
Out of 49 HDL proteins that significantly differed between
deaths and survivors, we selected 12 proteins to predict death
based on multiple statistical approaches. These 12 proteins notably
reflected, among others, processes related to atherogenesis,
inflammation, and oxidative stress. Not much is known about
their association with HF (outcome), but alpha-2-HS-glycoprotein
(also called fetuin-A) levels were found to be lower in chronic HF
patients,17 lower levels of APOA1 have been associated with worse
prognosis in HF,4,5 higher beta-2-microglobulin levels have been
proposed as a cardiovascular risk marker in HF,18 and decreased
PON1 activity and levels have been associated with HF and adverse
outcomes in HF.13,14,19 We will elaborate on FLNA, SFTPB, and
APOC3 in the next section.
The strongest contributors to the prediction model were FLNA
and SFTPB. We realise that the presence of these proteins in
the HDL proteome is not direct proof for their presence in the
heart, or for signalling in the heart, but nevertheless believe their
presence may have functional consequences to the heart related
to the associations we describe. First, FLNA is an actin-binding
protein that plays a role in cell signalling functions, such as cell
migration and organ development. Deficiency of FLNA is, among
others, associated with severe cardiac malformation, suggesting
an important function of FLNA in cardiac morphogenesis.20 In a
mouse model, endothelial deletion of FLNA resulted in a defective
endothelial response and increased scar formation, leading to
worse myocardial infarction-induced left ventricular dysfunction.21
These unfavourable effects of FLNA deficiency appear to be
reflected by the decreased abundances of FLNA in deaths in
our study.
Second, higher levels of SFTPB in deaths could be explained
by the presence of increased alveolar membrane damage in a
worse HF disease state due to increased pulmonary pressure,
resulting in oedema and subsequently in dyspnoea in HF. Levels
© 2017 The Authors
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Figure 2 S-plot of high-density lipoprotein (HDL) proteins. SIMCA14 was used to generate this figure based on orthogonal projections to
latent structures discriminant analysis scores for putative biomarker identification. In this figure, the p1-axis (x-axis) describes the magnitude of
each variable in the data and the p(corr)1-axis (y-axis) represents the reliability of each variable in the data. The selected proteins are indicated
in red while the remaining significantly different proteins between deaths and survivors are indicated in green. AHSG, alpha-2-HS-glycoprotein;
APOA1, apolipoprotein A-I; APOA2, apolipoprotein A-II; APOC3, apolipoprotein C-III; B2M, beta-2-microglobulin; EPHX1, epoxide hydrolase
1; F10, coagulation factor X; FLNA, filamin-A; MST1, macrophage-stimulating protein; PON1, serum paraoxonase/arylesterase 1; SERPINA4,
kallistatin; SFTPB, pulmonary surfactant-associated protein B.
of surfactant proteins in plasma, especially SFTPB, are suitable
biomarkers to assess lung health and alveolar capillary membrane
function, because when damaged, surfactant proteins move into the
blood.22–24 It is thus logical for SFTPB to be higher in a worse HF
disease state (reflecting increased congestion), which has moreover
been shown in HF before.25 Whether the HDL-bound portion of
SFTPB compared to SFTPB levels in plasma is a better predictor of
HF outcome is difficult to say since it is not entirely clear what
portion of the total amount of SFTPB binds to HDL, but in a
previous study investigating the HDL proteome in end-stage renal
disease (ESRD) patients, HDL-bound SFTPB was associated with
ESRD, while its plasma counterpart was comparable between ESRD
patients and chronic kidney disease stage 4 patients.26 It is thus
possible for the SFTPB HDL-bound portion to be different from
its plasma counterpart, which could possibly also be the case in
























.. Although most findings in this study are in line with the expected
observations, an unexpected finding was that APOC3 levels were
lower in deaths. Previous studies repeatedly showed that higher
APOC3 levels are consistent with higher cardiovascular event rates
due to its atherogenic effects. This has however predominantly
been investigated for non-HDL lipid particles (low-density lipopro-
tein and very low-density lipoprotein) and total plasma; data on
HDL APOC3 are too limited and inconsistent to confirm that the
same is true for these particles.27 However, as explained further on,
a satisfactory explanation for this finding remains uncertain due to
recovery of all lipoproteins by the used methodology.
Strengths and limitations of the study
This is the first study investigating HDL proteome composition
in relation to clinical outcome in patients with HF. The lipopro-
tein isolation method that was used in this study proved to be
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Figure 3 Receiver operating characteristic curve for prediction
of death. The blue curve represents all 12 selected proteins
combined. AUC, area under the curve.
highly suitable for addressing the aim of this study; we were
able to detect 88.4% out of the total number of confident HDL
proteins.
Furthermore, use of UPLC-HDMSE as a means to analyse pro-
teins ensured high selectivity, specificity and confidence. The meth-
ods of this study proved to be time-efficient, high-throughput,
reproducible, capable of working with complex samples and inex-
pensive (both the sample preparation procedure and the label-free
quantification approach). Reliability of the MS runs was ensured by
running quality controls and Hela cell extract and, on top of that,
use of powerful informatics to analyse the raw data. Finally, the
well-matched groups ensured suitable circumstances for discovery
purposes.
The fact that the survivors and the deaths groups were so well
matched could however also pose a limitation: after correction for
important influential factors such as age and severity of HF in a
non-matched patient cohort, the HDL proteome may lose some
of its predictive value. The matching used in this study cohort also
limited analysis of the additive value of the HDL proteome on top
of the recently constructed BIOSTAT risk score,6 since the groups
were already matched on some of the variables present.
Also, the results of this study only apply to patients of Cau-
casian ethnicity and HF patients with a reduced ejection fraction.
Furthermore, the lipid affinity matrix used in this study does not
have specific affinity for HDL alone and other lipid subclasses could
have potentially influenced the measured apolipoprotein amounts
to some extent. Finally, only 49 patients had available HDL choles-
terol measurements. However, we do not know whether the HDL
protein to cholesterol ratio is similar for every patient, which is why
there is no indication to say that this has certainly influenced our



















































































.. on the LC–MS/MS for each sample. As a surrogate for HDL choles-
terol, APOA1 is often used. We see in our analysis that APOA1
is lower in deaths in univariate and multivariate analysis, which is
in line with the association between lower HDL cholesterol and
adverse outcome in HF in the BIOSTAT-CHF study.
In order to address some limitations of this study, the following
studies could be carried out: (i) a validation study to confirm
the findings of this study in another study population; (ii) a study
investigating the relationship between HDL functionality in relation
with HDL proteome content and in relation to prognosis in HF; (iii)
a validation of the total plasma content of FLNA and SFTPB where
bound and free fractions can be calculated and independently
related to outcomes; and (iv) addition of HF hospitalisation as an
endpoint.
Conclusions and implications
This study shows that abundances of proteins with multiple impor-
tant functions that reflect, among others, atherogenesis, inflam-
mation, and oxidative stress, are altered in the HDL proteome of
patients with a worse HF disease state. The strongest differences
were seen in proteins reflecting crosslinking of actin filaments and
alveolar capillary membrane function. Therefore, HDL could be a
proxy for these processes implicated in HF pathophysiology which
might explain the association between low HDL and increased risk
of mortality and/or hospitalisation in patients with HF.
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